Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
- Nippon Kayaku’s Nambu Stresses Need for Collaboration between Medium-Sized Companies in Biosimilars
January 26, 2012
- Taiyo, Teva-Kowa to Establish Teva Pharma Japan in April, with 7 Branches, 29 Sales Offices Nationwide
January 26, 2012
- 301 MSs from Medipal HD Pass 18th MR Examination
January 26, 2012
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
- Nichi-Iko, Sanofi to Jointly Develop Remicade Biosimilar
January 25, 2012
- Pfizer Japan Launches Zithromac for Intravenous Use
January 25, 2012
- CMIC HD to Merge 2 CRO Subsidiaries
January 25, 2012
- Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
- Seikagaku Initiates PII Trial for SI-614 for Dry Eye in US
January 24, 2012
- Sosei Announces Collaboration with CEOLIA Pharma
January 24, 2012
- Wakamoto Pharmaceutical Withholds Joint Venture Plan with Major Taiwanese Generics Company
January 23, 2012
- Astellas to Transfer 3 Drugs to Choseido including Tathion
January 23, 2012
- Indications for Alveolar Pyorrhea Removed from Lysozyme HCl
January 23, 2012
- Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
- NPhA’s Iwasaki Says Strength in Securing Profit Weak
January 23, 2012
- GSK Obtains Approval for Paxil CR Tablets, to Comarket with DSP
January 20, 2012
- No. of Patients Not Recommended to Take Generics Down to 40%: Sawai Survey
January 20, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…